Intelligent Bio Solutions announced it has received a second progress payment of $1.43M as part of a scientific grant awarded to the Company in 2021 for $4.7M, as announced by the Company on July 8, 2021. The latest payment brings the total funds received to date to $3.25M. The Medical Products Priority Grant, from the Australian Federal Government’s Department of Industry, Science, Energy and Resources’ Modern Manufacturing Initiative, which is subject to conditions and achieving certain deliverables, was awarded to fund the establishment of a state-of-the-art Australian medical device manufacturing facility. The Australian Government identified the project as one of six National Manufacturing Priorities under the Modern Manufacturing Strategy, MMS. “We are grateful for the continued support from the Australian Federal Government,” said Harry Simeonidis, President and CEO of Intelligent Bio Solutions. “This second progress payment demonstrates the Australian Government’s commitment to the development of high-tech medical devices and solutions by Australian medical companies.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on INBS:
- Intelligent Bio Solutions Receives Non-Dilutive Grant Funding of USD $1.43 Million
- Intelligent Bio Solutions Plans to Add Fentanyl Testing as it Further Enhances its Fingerprint-Based Drug Screening Solution
- Intelligent Bio Solutions Inc. Reports Fiscal 2023 Third Quarter Financial Results and Operational Highlights
- Intelligent Bio recruits four sales executives for sales force in Australia
- Intelligent Bio Solutions Scales Reach Throughout Asia-Pacific Region with Addition of Sales Team in Australia, New Distribution Hub and Office Facility
